GS-9620 CAS 1228585-88-3

Name

GS-9620

Synonyms

4-Amino-2-butoxy-7,8-dihydro-8-[[3-(1-pyrrolidinylmethyl)phenyl]methyl]-6(5H)-pteridinone;8-(3-(pyrrolidin-1-ylMethyl)benzyl)-4-aMino-2-butoxy-7,8-dihydropteridin-6(5H)-one;MFCD25372045 (GS-9620);4-Amino-2-butoxy-7,8-dihydro-8-[[3-(1-pyrrolidinylmethyl)phenyl]methyl]-6(5H)-pteridinone GS 9620;GS9620

Molecular Formula

C22H30N6O2

Molecular Weight

410.51

CAS Number (Or Watson Number for Non-CAS Products)

1228585-88-3

EINECS

Specs/Standards

98%min

Use

GS-9620 is a potent and selective orally active small molecule agonist of Toll-like receptor 7(TLR-7) in chimpanzees with chronic HBV infection. IC50 Value: Target: TLR7 GS-9620 is a novel oral agonist of Toll-like receptor 7 (TLR7) in development for the treatment of chronic viral hepatitis. TLR7 is a highly conserved innate immune receptor expressed primarily on plasmacytoid dendritic cells and B lymphocytes. in vitro: in vivo: Short-term oral administration of GS-9620 provided long-term suppression of serum and liver HBV DNA. The mean maximum reduction of viral DNA was 2.2 logs, which occurred within 1 week of the end of GS-9620 administration; reductions of >1 log persisted for months. Serum levels of HBV surface antigen and HBV e antigen, and numbers of HBV antigen-positive hepatocytes, were reduced as hepatocyte apoptosis increased. GS-9620 administration induced production of interferon-¦Á and other cytokines and chemokines, and activated interferon-stimulated genes, natural killer cells, and lymphocyte subsets. Induction of chemokines/cytokines and IFN-stimulated genes were seen at GS-9620 doses ¡Ý2 mg, well below doses that induced serum IFN-¦Á or led to clinical adverse events. Clinical trial: A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B. Phase 2.

Sales Link

This product is exclusively sold through our sales company Watson International Ltd and please refer to the link below for inquiries
http://watson-int.com/GS-9620-cas-1228585-88-3/